Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
69 people get IG articles and Market Currents by email alert.
Get email alerts on IG »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 11, 2013)
-
Business Wire (Apr 5, 2013)
-
Business Wire (Apr 4, 2013)
-
-
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 20, 2013)
-
Business Wire (Feb 15, 2013)
-
Business Wire (Feb 4, 2013)
-
Business Wire (Jan 28, 2013)
-
Business Wire (Jan 4, 2013)
-
Business Wire (Dec 27, 2012)
-
Business Wire (Dec 19, 2012)
-
Business Wire (Nov 13, 2012)
-
Business Wire (Nov 13, 2012)
-
Business Wire (Nov 5, 2012)
-
Business Wire (Nov 1, 2012)
To learn more about Seeking Alpha Pro, click here.
There are no Focus articles on IG.
-
IGI Ongoing Business Update Call TranscriptMon, Dec 17, 2007
-
Business Wire (Apr 25, 2013)
-
Business Wire (Apr 11, 2013)
-
Business Wire (Apr 5, 2013)
-
Business Wire (Apr 4, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 20, 2013)
-
Business Wire (Feb 15, 2013)
-
Business Wire (Feb 4, 2013)
-
Business Wire (Jan 28, 2013)
-
Business Wire (Jan 4, 2013)
-
Business Wire (Dec 27, 2012)
-
Business Wire (Dec 19, 2012)
-
Business Wire (Nov 13, 2012)
-
Business Wire (Nov 13, 2012)
-
Business Wire (Nov 5, 2012)
-
Business Wire (Nov 1, 2012)
-
Business Wire (Sep 6, 2012)
-
Business Wire (Aug 13, 2012)
-
Business Wire (Aug 2, 2012)
IG vs. ETF Alternatives
Company Description
Currently, there's no company description for IG.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, April 25, 6:46 PM IGI Laboratories (IG): Q1 EPS of -$0.01 misses by $0.01. Revenue of $3.68M beats by $1.28M. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Monday, March 18, 12:48 PM
Midday top 10 gainers: YRCW +25%. PRWT +22%. ULTR +17%. IG +17%. CHYR +16%. ATOS +14%. TA +13%. NYMX +13%. WILC +11%. SORL +11%.
Midday top 10 losers: AMBO -19%. PTX -12%. SOL -10%. CNET -10%. EMITF -9%. TSEM -8%. MNDO -8%. RGDX -8%. JVA -8%. AMBA -8%. 1 Comment [On the Move] - Tuesday, March 5, 4:35 PM IGI Laboratories (IG): Q4 EPS of -$0.03 misses by $0.03. Revenue of $2.3M (+10% Y/Y) in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, February 15, 11:58 AM IGI Laboratories (IG +2.2%) trades up after signing a three-year agreement with Juventio LLC to manufacture and supply finished dose forms of certain cosmetic and OTC products and formulations owned and developed by IGI. The products utilize encapsulation technology trademarked as Novasome for which the company currently holds an exclusive license. Comment! [Healthcare, On the Move]
- Tuesday, November 13, 2012, 4:28 PM IGI Laboratories (IG): Q3 EPS of -$0.04 misses by $0.04. Revenue of $1.99M (-6% Y/Y) misses by $1.3M. (PR) Comment! [Earnings, Healthcare]
- Friday, September 21, 2012, 3:25 PM Another tale in the frenzy for yield, Mexican chemical giant Mexichem sees a whopping $17.5B in bids for $1.15B in long-term notes. A healthy transaction, says HSBC's Katia Bouzaaz, is 2.5-3.5X, and 5X is considered high, but 15X is unheard of. "It's a chase for yields ... 6.75% for 30-year (IG) paper is pretty attractive." Smiles abound at the Eccles Building. Comment! [Global & FX]
- Friday, June 29, 2012, 4:20 PM IGI Laboratories (IG) says it's submitted two additional abbreviated new drug applications to the FDA, bringing the company's total number of submissions to eight. Comment! [Healthcare]
-
Michael Terry
Companies have issued $47B of debt in May, down from $183B in April and the least since Dec. 1999. IG CDX is out 45 from tights. - View all 0 replies
-
Michael Terry
3M LIBOR bumping against 50bps, CDX IG inching up again 125.5/126.5. Germany's vote not helping credit confidence - View all 0 replies
-
David White
Ben Potter (IG Mkts): Many European-focused airlines, already weak financially,are going to suffer very badly from this volcanic disaster. - View all 0 replies
-
- View all 0 replies
LATEST REPLIES